ISA Pharmaceuticals
ISA Pharmaceuticals was founded in 2004 by Aglaia Oncology Fund and is based in Leiden Bio Science Park. The company has a strong scientific foundation and a proven track record of clinical development. ISA Pharmaceuticals has a diverse pipeline of SLP immunotherapies for various indications, such as cervical cancer, head and neck cancer, uveal melanoma, and COVID-19. ISA Pharmaceuticals reported revenue of $7.4 million for FY 2022
One of the most advanced products of ISA Pharmaceuticals is ISA101b, an SLP immunotherapy that targets human papillomavirus (HPV) type 16, which is responsible for about 70% of cervical cancers and 90% of oropharyngeal cancers. ISA101b has shown promising results in phase 2 clinical trials in combination with cemiplimab (Libtayo®), a PD-1 inhibitor, in patients with platinum-refractory HPV16 positive oropharyngeal cancer. The company has completed the enrolment of 150 patients in a randomized double-blind phase 2 trial and expects to report the results in 2023.
ISA Pharmaceuticals has received several awards and recognitions for its achievements and contributions to the field of immunotherapy. The company was awarded the Prix Galien Medtech Award in 2016 for its SLP technology. The company was also named one of the Top 10 Most Innovative Companies in Europe by Fast Company in 2017. Moreover, the company's co-founder and chief scientific officer, Prof. Cornelis Melief, was awarded the European Inventor Award in 2019 for his pioneering work on SLP immunotherapy.
Foundation: 2004
Headquarters: Leiden, South Holland, Netherlands.
Website: https://www.isa-pharma.com/
